Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?

Given the growing number of patients receiving direct oral anticoagulant (DOAC), patients requiring rapid neutralization is also increasing in case of major bleedings or urgent surgery/procedures. Idarucizumab is commercialized as a specific antidote to dabigatran while andexanet alfa has gained the Food and Drug Administration and the European Medicines Agency approval as an oral anti-factor Xa inhibitors antidote. Other antidotes or hemostatic agents are still under preclinical or clinical development, the most advanced being ciraparantag.

Source: Thrombosis Research - April 9, 2024 Category: Hematology Authors: Nicolas Gendron, Paul Billoir, Virginie Siguret, V éronique Le Cam-Duchez, Valérie Proulle, Laurent Macchi, Elodie Boissier, Christine Mouton, Emmanuel De Maistre, Isabelle Gouin-Thibault, Georges Jourdi, French Society on Thrombosis and Haemostasis Source Type: research